Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Deal Details

C/PIndustryStatusTicker(s)Issuer(s)Size(m)TranchesRegionDate
IGC
HLTH
PRCD
HALEON
GSK Consumer Healthcare Capital NL BV€2,350
3EMEA
Mar 22, 2022
currency
EUR
size (m)
850.000
maturity
Mar 29, 2026
type
Fixed
tenor
4.000
call
-
registration
Reg S Only
benchmark
Swaps
ranking
Sr. Unsecured
moody's
Baa1
s&p
BBB
fitch
-
size description
-
re-open/tap
No
ipt
MS+90 a
ipt-pxd
-
guidance
MS+65 a
spread
55
coupon
1.25%
spread set
-
price
99.80600
yield
1.3%
book size (m)
3,600
peak book (m)
-
x-covered
4.24
book attrition
-
nic
-
billing & delivering
active leads
-
joint leads
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
3,600
peak book (m)
-
x-covered
4.24
book attrition
-
nic
-
billing & delivering
active leads
-
joint leads
passive leads
-
co-managers
-
coordinating managers
-
currency
EUR
size (m)
750.000
maturity
Mar 29, 2030
type
Fixed
tenor
6.000
call
-
registration
Reg S Only
benchmark
Swaps
ranking
Sr. Unsecured
moody's
Baa1
s&p
BBB
fitch
-
size description
-
re-open/tap
No
ipt
MS+120 a
ipt-pxd
-
guidance
MS+90 a
spread
75
coupon
1.75%
spread set
-
price
99.89600
yield
1.764%
book size (m)
3,900
peak book (m)
-
x-covered
5.2
book attrition
-
nic
-
billing & delivering
active leads
-
joint leads
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
3,900
peak book (m)
-
x-covered
5.2
book attrition
-
nic
-
billing & delivering
active leads
-
joint leads
passive leads
-
co-managers
-
coordinating managers
-
currency
EUR
size (m)
750.000
maturity
Mar 29, 2034
type
Fixed
tenor
12.000
call
-
registration
Reg S Only
benchmark
Swaps
ranking
Sr. Unsecured
moody's
Baa1
s&p
BBB
fitch
-
size description
-
re-open/tap
No
ipt
MS+140 a
ipt-pxd
-
guidance
MS+110 a
spread
100
coupon
2.125%
spread set
-
price
99.27900
yield
2.194%
book size (m)
3,600
peak book (m)
-
x-covered
4.8
book attrition
-
nic
-
billing & delivering
active leads
-
joint leads
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
3,600
peak book (m)
-
x-covered
4.8
book attrition
-
nic
-
billing & delivering
active leads
-
joint leads
passive leads
-
co-managers
-
coordinating managers
-
Tranche Comments
4 yr: Book size: 3600; Registration: Reg S Only; Comments: EUR850m(upsized from EUR750m) 3-prt bmk snr unsec RegS. Baa1/BBB/-. DB(B&D)/BofA/GS/Barc/MS. With GBP 2-prt. IPTs: 4yr MS+90a, 6yr MS+120a, 12yr MS+140a. Guidance MS+65a/MS+90a/MS+110a for exp 750m each, launch 850m MS+55, 750m MS+75, 750m MS+100, bks >3.6bn/>3.9bn/?3.6bn, peak >3.8bn/>5.3bn/>4.4bn. DBR 0½ 2/26 | DBR 0 2/30 | DBR 0 2/32 101.70 | 97.22 | 95.18 | B+123.7 | B+140.6 | B+169.4 HR: 98% | 97% | 111% |. LEI: 549300RXQZBOJONY3Q97. CoC: 100%; 6 yr: Book size: 3900; Registration: Reg S Only; Comments: EUR750m 3-prt bmk snr unsec RegS. Baa1/BBB/-. DB(B&D)/BofA/GS/Barc/MS. With GBP 2-prt. IPTs: 4yr MS+90a, 6yr MS+120a, 12yr MS+140a. Guidance MS+65a/MS+90a/MS+110a for exp 750m each, launch 850m MS+55, 750m MS+75, 750m MS+100, bks >3.6bn/>3.9bn/?3.6bn, peak >3.8bn/>5.3bn/>4.4bn. DBR 0½ 2/26 | DBR 0 2/30 | DBR 0 2/32 101.70 | 97.22 | 95.18 | B+123.7 | B+140.6 | B+169.4 HR: 98% | 97% | 111% |. LEI: 549300RXQZBOJONY3Q97. CoC: 100%; 12 yr: Book size: 3600; Registration: Reg S Only; Comments: EUR750m 3-prt bmk snr unsec RegS. Baa1/BBB/-. DB(B&D)/BofA/GS/Barc/MS. With GBP 2-prt. IPTs: 4yr MS+90a, 6yr MS+120a, 12yr MS+140a. Guidance MS+65a/MS+90a/MS+110a for exp 750m each, launch 850m MS+55, 750m MS+75, 750m MS+100, bks >3.6bn/>3.9bn/?3.6bn, peak >3.8bn/>5.3bn/>4.4bn. DBR 0½ 2/26 | DBR 0 2/30 | DBR 0 2/32 101.70 | 97.22 | 95.18 | B+123.7 | B+140.6 | B+169.4 HR: 98% | 97% | 111% |. LEI: 549300RXQZBOJONY3Q97. CoC: 100%;
Guarantor(s)
GlaxoSmithKline PLC
Use of Proceeds
To fund pre-demerger dividends

Commentary

Explore all other Commentary & Deal Flow

Deal Flow

Explore all other Commentary & Deal Flow
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.